Mr Tom Speedy
Innova Biosciences Ltds core business is bioconjugation (antibody labeling) the joining of two molecules to form a hybrid conjugate™. Conjugates are used in hospital and research labs around the world; they also feature in consumer items such as pregnancy test kits (the conjugate is responsible for the blue line). Innova™s one-step conjugation method (Lightning-Link) massively simplifies the production of conjugates that are needed for research and immunodiagnostic applications. Innova also offers exclusive services for optimizing the performance of conjugates and developing more sensitive immunodiagnostic tests. Innova also sells several niche products to pharmaceutical research and development labs.
Mr David Spillett
Penn services include: CMC Consultancy, Formulation Development, Analytical Development, Clinical Trial Supply, Contract Manufacturing, Qualified Persons Release Services, Paediatrics Formulation and Manufacturing, Hi-Potency capabilities, Orphan drug expertise, More than 30 Years of specials, manufacturing expertise, Comparator Sourcing.
The above offerings are all under one roof providing a strong and easy communication channel between departments making developments, manufacturing and analytical processes.
Dr Alasdair Stamps
BioPartner.co.uk is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's UK Delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists companies to attend these events by providing access to government grants and heavily discounted entry fees.
Mr David Sykes
NextPharma Technologies is a world class outsourcing partner to the pharmaceutical and biotechnology industries.
We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing of New Chemical Entities (NCEs) and generic products. NextPharma is a world leader in pellet technologies and in specialist product manufacturing including hormones, penicillins, cephalosporins and controlled drugs. We are experts in paediatric drug formulation, development and manufacture. In addition to these specialist areas we have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.
NextPharma offers ‘one-stop’ logistics solutions tailored to meet the needs of the global pharmaceutical industry under the rigid standards of cGSP/GDP regulations.
NextPharma operates globally with six product development centres, six manufacturing plants and seven temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan. We employ 1,000 people dedicated to serving over 200 customers world wide and a customer base, which includes many of the world’s leading pharmaceutical, specialty pharma and biotechnology companies.
All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.